CY1113376T1 - Παραγωγα της φαινυλο-[1,2,4]-οξαδιαζολ-5-ονης με ομαδα φαινυλιου, διαδικασιες για την παρασκευη τους και η χρηση τους ως φαρμακα - Google Patents
Παραγωγα της φαινυλο-[1,2,4]-οξαδιαζολ-5-ονης με ομαδα φαινυλιου, διαδικασιες για την παρασκευη τους και η χρηση τους ως φαρμακαInfo
- Publication number
- CY1113376T1 CY1113376T1 CY20121101040T CY121101040T CY1113376T1 CY 1113376 T1 CY1113376 T1 CY 1113376T1 CY 20121101040 T CY20121101040 T CY 20121101040T CY 121101040 T CY121101040 T CY 121101040T CY 1113376 T1 CY1113376 T1 CY 1113376T1
- Authority
- CY
- Cyprus
- Prior art keywords
- finish
- oxadiazol
- disorders
- preparation
- procedures
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- LMBDRBXGTCUBIH-UHFFFAOYSA-N 3-phenyl-2h-1,2,4-oxadiazol-5-one Chemical class N1OC(=O)N=C1C1=CC=CC=C1 LMBDRBXGTCUBIH-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021235 | 2005-09-29 | ||
| EP06792252A EP1931660B1 (en) | 2005-09-29 | 2006-09-26 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113376T1 true CY1113376T1 (el) | 2016-06-22 |
Family
ID=35809809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121101040T CY1113376T1 (el) | 2005-09-29 | 2012-10-31 | Παραγωγα της φαινυλο-[1,2,4]-οξαδιαζολ-5-ονης με ομαδα φαινυλιου, διαδικασιες για την παρασκευη τους και η χρηση τους ως φαρμακα |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7834030B2 (https=) |
| EP (2) | EP1934206B1 (https=) |
| JP (2) | JP5183479B2 (https=) |
| KR (2) | KR20080048520A (https=) |
| CN (2) | CN101268069A (https=) |
| AR (2) | AR056541A1 (https=) |
| AT (1) | ATE537167T1 (https=) |
| AU (2) | AU2006299092A1 (https=) |
| BR (2) | BRPI0616465A2 (https=) |
| CA (2) | CA2624105C (https=) |
| CR (1) | CR9784A (https=) |
| CY (1) | CY1113376T1 (https=) |
| DK (1) | DK1931660T3 (https=) |
| DO (2) | DOP2006000204A (https=) |
| EC (1) | ECSP088323A (https=) |
| ES (1) | ES2392181T3 (https=) |
| IL (2) | IL190228A0 (https=) |
| MA (2) | MA29804B1 (https=) |
| MY (2) | MY148982A (https=) |
| NO (2) | NO20081367L (https=) |
| NZ (2) | NZ566878A (https=) |
| PE (2) | PE20070545A1 (https=) |
| PL (1) | PL1931660T3 (https=) |
| PT (1) | PT1931660E (https=) |
| RU (2) | RU2008112201A (https=) |
| SI (1) | SI1931660T1 (https=) |
| TN (1) | TNSN08145A1 (https=) |
| TW (2) | TWI398436B (https=) |
| UY (2) | UY29830A1 (https=) |
| WO (2) | WO2007039172A1 (https=) |
| ZA (1) | ZA200801630B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| JP5373613B2 (ja) | 2006-10-16 | 2013-12-18 | バイオノミクス リミテッド | 新規な抗不安薬化合物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US10793515B2 (en) * | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US20210130285A1 (en) * | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CA2828780A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2707367B1 (en) | 2011-05-12 | 2019-10-09 | Bionomics Limited | Methods for preparing naphthyridines |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| RU2014133738A (ru) | 2012-01-18 | 2016-03-10 | Дайити Санкио Компани, Лимитед | Замещенное производное фенилазола |
| WO2013186089A2 (en) | 2012-06-14 | 2013-12-19 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests |
| US10258672B2 (en) | 2014-10-09 | 2019-04-16 | Case Western Reserve University | Compositions and methods of treating root avulsion injury |
| CN106616029B (zh) * | 2016-12-08 | 2020-05-01 | 西南大学 | 一种提高虹鳟抗病能力的饲料添加剂及其制备方法 |
| CN108976150B (zh) * | 2017-06-05 | 2022-11-18 | 重庆博腾制药科技股份有限公司 | 一种3-乙基-4-氟苯腈的制备方法 |
| CN111093684A (zh) * | 2017-07-11 | 2020-05-01 | 凯斯西储大学 | 用于治疗髓鞘病症的组合物和方法 |
| KR102919209B1 (ko) | 2018-08-10 | 2026-01-28 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| EP4211139A4 (en) | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| WO2025237291A1 (zh) * | 2024-05-13 | 2025-11-20 | 上海翰森生物医药科技有限公司 | 一种异丙基异喹啉类化合物的制备方法及其中间体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| ES2277842T3 (es) * | 1999-06-18 | 2007-08-01 | MERCK & CO., INC. | Derivados de ariltiazolidindiona y de ariloxazolidindiona. |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| AU2002323776B2 (en) * | 2001-08-10 | 2008-07-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor Delta |
| ES2290439T3 (es) * | 2002-02-25 | 2008-02-16 | Eli Lilly And Company | Moduladores del receptor activado del proliferador de peroxisomas. |
| JPWO2004080943A1 (ja) | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| EP1690538A4 (en) | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
-
2006
- 2006-09-26 AU AU2006299092A patent/AU2006299092A1/en not_active Abandoned
- 2006-09-26 CN CNA2006800344489A patent/CN101268069A/zh active Pending
- 2006-09-26 EP EP06805857A patent/EP1934206B1/en active Active
- 2006-09-26 CA CA2624105A patent/CA2624105C/en not_active Expired - Fee Related
- 2006-09-26 NZ NZ566878A patent/NZ566878A/en not_active IP Right Cessation
- 2006-09-26 JP JP2008532648A patent/JP5183479B2/ja not_active Expired - Fee Related
- 2006-09-26 DK DK06792252.6T patent/DK1931660T3/da active
- 2006-09-26 CA CA002624093A patent/CA2624093A1/en not_active Abandoned
- 2006-09-26 PL PL06792252T patent/PL1931660T3/pl unknown
- 2006-09-26 NZ NZ566875A patent/NZ566875A/en not_active IP Right Cessation
- 2006-09-26 KR KR1020087007735A patent/KR20080048520A/ko not_active Withdrawn
- 2006-09-26 SI SI200631453T patent/SI1931660T1/sl unknown
- 2006-09-26 WO PCT/EP2006/009298 patent/WO2007039172A1/en not_active Ceased
- 2006-09-26 RU RU2008112201/04A patent/RU2008112201A/ru not_active Application Discontinuation
- 2006-09-26 PT PT06792252T patent/PT1931660E/pt unknown
- 2006-09-26 AT AT06805857T patent/ATE537167T1/de active
- 2006-09-26 WO PCT/EP2006/009304 patent/WO2007039178A2/en not_active Ceased
- 2006-09-26 ES ES06792252T patent/ES2392181T3/es active Active
- 2006-09-26 JP JP2008532645A patent/JP2009509986A/ja not_active Abandoned
- 2006-09-26 RU RU2008112202/04A patent/RU2008112202A/ru not_active Application Discontinuation
- 2006-09-26 BR BRPI0616465-0A patent/BRPI0616465A2/pt not_active Application Discontinuation
- 2006-09-26 BR BRPI0616457-9A patent/BRPI0616457A2/pt not_active IP Right Cessation
- 2006-09-26 EP EP06792252A patent/EP1931660B1/en active Active
- 2006-09-26 CN CNA2006800359450A patent/CN101273036A/zh active Pending
- 2006-09-26 AU AU2006299086A patent/AU2006299086A1/en not_active Abandoned
- 2006-09-27 MY MYPI20064224A patent/MY148982A/en unknown
- 2006-09-27 DO DO2006000204A patent/DOP2006000204A/es unknown
- 2006-09-27 TW TW095135660A patent/TWI398436B/zh not_active IP Right Cessation
- 2006-09-27 MY MYPI20064223A patent/MY149182A/en unknown
- 2006-09-27 AR ARP060104222A patent/AR056541A1/es not_active Application Discontinuation
- 2006-09-27 TW TW095135657A patent/TW200811154A/zh unknown
- 2006-09-27 AR ARP060104225A patent/AR056203A1/es not_active Application Discontinuation
- 2006-09-27 DO DO2006000205A patent/DOP2006000205A/es unknown
- 2006-09-28 PE PE2006001178A patent/PE20070545A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29830A patent/UY29830A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29829A patent/UY29829A1/es not_active Application Discontinuation
- 2006-09-29 PE PE2006001189A patent/PE20070768A1/es not_active Application Discontinuation
-
2008
- 2008-02-19 ZA ZA2008/01630A patent/ZA200801630B/en unknown
- 2008-02-29 CR CR9784A patent/CR9784A/es not_active Application Discontinuation
- 2008-03-14 NO NO20081367A patent/NO20081367L/no not_active Application Discontinuation
- 2008-03-14 NO NO20081370A patent/NO20081370L/no not_active Application Discontinuation
- 2008-03-17 IL IL190228A patent/IL190228A0/en unknown
- 2008-03-17 IL IL190227A patent/IL190227A/en not_active IP Right Cessation
- 2008-03-24 MA MA30780A patent/MA29804B1/fr unknown
- 2008-03-24 MA MA30783A patent/MA29807B1/fr unknown
- 2008-03-25 KR KR1020087007148A patent/KR101342415B1/ko not_active Expired - Fee Related
- 2008-03-26 US US12/055,764 patent/US7834030B2/en not_active Expired - Fee Related
- 2008-03-26 US US12/055,793 patent/US20080287409A1/en not_active Abandoned
- 2008-03-27 EC EC2008008323A patent/ECSP088323A/es unknown
- 2008-03-28 TN TNP2008000145A patent/TNSN08145A1/en unknown
-
2009
- 2009-05-29 US US12/474,838 patent/US7851493B2/en not_active Expired - Fee Related
-
2012
- 2012-10-31 CY CY20121101040T patent/CY1113376T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113376T1 (el) | Παραγωγα της φαινυλο-[1,2,4]-οξαδιαζολ-5-ονης με ομαδα φαινυλιου, διαδικασιες για την παρασκευη τους και η χρηση τους ως φαρμακα | |
| CY1121639T1 (el) | Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων | |
| TW200635899A (en) | Chemical compounds | |
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| MX2007008924A (es) | Compuestos quimicos. | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| TW200634003A (en) | Chemical compounds | |
| MX2009004908A (es) | Compuestos quimicos. | |
| TW200616974A (en) | Chemical compounds | |
| IL173203A0 (en) | Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament | |
| WO2009003999A3 (en) | Chemical compounds | |
| CY1109370T1 (el) | Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| MX2008013212A (es) | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| ECSP088322A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
| TW200621259A (en) | Chemical compounds | |
| MY139107A (en) | Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments. | |
| TW200508210A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| WO2007009720A3 (en) | Prodrugs of pyrazoline compounds, their preparation and use as medicaments | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| MX2009007889A (es) | Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. | |
| MX2009013482A (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas. | |
| WO2010031708A3 (en) | Ortho-aminoanilides for the treatment of cancer | |
| MX2009005912A (es) | Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos. |